Sotagliflozin Shows Breakthrough 23% Reduction in Heart Attack and Stroke Risk for Diabetic Kidney Disease Patients
• A landmark clinical trial led by Mount Sinai researchers demonstrates that sotagliflozin, a dual SGLT1/2 inhibitor, reduces heart attacks, strokes, and cardiovascular deaths by 23% in patients with type 2 diabetes and chronic kidney disease.
• The SCORED trial, involving 10,584 patients, reveals a unique mechanism of action through combined SGLT1 and SGLT2 blockade, distinguishing it from existing SGLT2 inhibitors currently in clinical use.
• Recently FDA-approved sotagliflozin offers physicians a new treatment option for reducing cardiovascular risks in patients with heart failure or type 2 diabetes with chronic kidney disease.
Osteosarcoma Subtypes Identified Using Novel Machine Learning Approach
• Researchers have identified three distinct subtypes of osteosarcoma using advanced mathematical modeling and machine learning, potentially revolutionizing clinical trials and patient care.
• The study utilized Latent Process Decomposition (LPD) to categorize osteosarcoma patients based on their genetic data, addressing the limitations of previous methods that treated all patients uniformly.
• One identified subtype showed poor response to the standard chemotherapy regimen MAP, suggesting the potential for tailored treatments based on subtype classification.
• The LPD method's reliability was demonstrated across four independent datasets, offering hope for improved clinical trial outcomes and a shift towards targeted therapies for osteosarcoma.
Filgotinib Fails to Meet Key Endpoints in Phase III Crohn's Disease Trial
• A Phase III trial (DIVERSITY) of filgotinib in Crohn's disease showed mixed results, failing to meet several primary endpoints for clinical remission and endoscopic response in induction studies.
• In biologic-experienced patients, filgotinib 200mg achieved statistically significant clinical remission at week 10 compared to placebo (30% vs 18%, P=0.0039), but not in biologic-naive patients.
• During the maintenance phase at 58 weeks, filgotinib 200mg demonstrated significant clinical and endoscopic remission compared to placebo (44% vs 26%, P=0.038 and 30% vs 9%, P=0.0038, respectively).
• Experts suggest study design limitations, such as early endoscopic assessment and high corticosteroid use, may have masked filgotinib's efficacy, warranting further investigation.
© Copyright 2025. All Rights Reserved by MedPath